Arterra Bioscience SpA (MIL:ARBS) Beneish M-Score: -2.15 (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:ARBS Arterra Bioscience SpA MIL:ARBS
77 GF Score
Price €3.04
GF Value €2.91
Valuation Fairly Valued
View Full Analysis

What is Arterra Bioscience SpA Beneish M-Score?

Arterra Bioscience SpA MIL:ARBS -0.33% 77 Beneish M-Score is -2.15 as of Jul. 19, 2026. GuruFocus rates MIL:ARBS with a GF Score™ of 77/100 and a GF Value™ of €2.91 (Fairly Valued). Among 824 Biotechnology companies, Arterra Bioscience SpA ranks worse than 57.28% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.15 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Arterra Bioscience SpA's Beneish M-Score or its related term are showing as below:

MIL:ARBS' s Beneish M-Score Range Over the Past 10 Years
Min: -2.99   Med: -2.15   Max: -1.66
Current: -2.15

During the past 9 years, the highest Beneish M-Score of Arterra Bioscience SpA was -1.66. The lowest was -2.99. And the median was -2.15.


Arterra Bioscience SpA Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Arterra Bioscience SpA's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arterra Bioscience SpA Beneish M-Score Chart

Arterra Bioscience SpA Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only -2.22 -2.68 -1.66 -1.78 -2.15

Arterra Bioscience SpA Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.66 0.00 -1.78 0.00 -2.15

MIL:ARBS vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Arterra Bioscience SpA's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arterra Bioscience SpA Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arterra Bioscience SpA's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Arterra Bioscience SpA's Beneish M-Score falls into.


MIL:ARBS
77GF Score
Arterra Bioscience SpA MIL:ARBS
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arterra Bioscience SpA Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Arterra Bioscience SpA for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9594+0.528 * 0.9432+0.404 * 1.5257+0.892 * 1.1275+0.115 * 1.2468
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1+4.679 * 0.00096-0.327 * 0.889
=-2.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was €3.50 Mil.
Revenue was €4.71 Mil.
Gross Profit was €4.36 Mil.
Total Current Assets was €6.83 Mil.
Total Assets was €14.59 Mil.
Property, Plant and Equipment(Net PPE) was €1.68 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.29 Mil.
Selling, General, & Admin. Expense(SGA) was €0.00 Mil.
Total Current Liabilities was €0.88 Mil.
Long-Term Debt & Capital Lease Obligation was €0.17 Mil.
Net Income was €2.01 Mil.
Gross Profit was €0.00 Mil.
Cash Flow from Operations was €1.99 Mil.
Total Receivables was €3.23 Mil.
Revenue was €4.17 Mil.
Gross Profit was €3.65 Mil.
Total Current Assets was €8.23 Mil.
Total Assets was €13.40 Mil.
Property, Plant and Equipment(Net PPE) was €1.51 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.34 Mil.
Selling, General, & Admin. Expense(SGA) was €0.00 Mil.
Total Current Liabilities was €0.82 Mil.
Long-Term Debt & Capital Lease Obligation was €0.26 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(3.496 / 4.705) / (3.232 / 4.173)
=0.743039 / 0.774503
=0.9594

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(3.65 / 4.173) / (4.363 / 4.705)
=0.874671 / 0.927311
=0.9432

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (6.825 + 1.68) / 14.588) / (1 - (8.231 + 1.508) / 13.402)
=0.416987 / 0.273317
=1.5257

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=4.705 / 4.173
=1.1275

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.339 / (0.339 + 1.508)) / (0.29 / (0.29 + 1.68))
=0.183541 / 0.147208
=1.2468

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 4.705) / (0 / 4.173)
=0 / 0
=1

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.167 + 0.882) / 14.588) / ((0.26 + 0.824) / 13.402)
=0.071908 / 0.080883
=0.889

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(2.006 - 0 - 1.992) / 14.588
=0.00096

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Arterra Bioscience SpA has a M-score of -2.15 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.15 mean?
Arterra Bioscience SpA (MIL:ARBS) has a Beneish M-Score of -2.15 as of Jul. 19, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Arterra Bioscience SpA and its competitors. According to the industry distribution chart, Arterra Bioscience SpA ranks #472 out of 824 companies in the Biotechnology industry, placing it in the top 57.3%.
Is Arterra Bioscience SpA's Beneish M-Score too high?
Arterra Bioscience SpA's current Beneish M-Score is -2.15. Based on the distribution chart, Arterra Bioscience SpA ranks #472 out of 824 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Arterra Bioscience SpA has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Arterra Bioscience SpA's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arterra Bioscience SpA ranks #472 out of 824 companies for Beneish M-Score. This places Arterra Bioscience SpA in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Arterra Bioscience SpA and its competitors. Arterra Bioscience SpA's current Beneish M-Score is -2.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arterra Bioscience SpA stock overvalued right now?
Based on GuruFocus' analysis, Arterra Bioscience SpA (MIL:ARBS) is currently considered Fairly Valued. The stock's GF Value™ is €2.91, compared to a current price of €3.04 — trading 4.5% above its estimated fair value. The current Beneish M-Score is -2.15. Arterra Bioscience SpA's overall GF Score™ is 77/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Arterra Bioscience SpA (MIL:ARBS), the current Beneish M-Score is -2.15 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arterra Bioscience SpA (MIL:ARBS) Overvalued in 2026?

Based on GuruFocus' analysis, Arterra Bioscience SpA stock appears to be overvalued. The current stock price of €3.04 is trading 4.5% above its estimated GF Value™ of €2.91. GuruFocus considers Arterra Bioscience SpA to be Fairly Valued.

Key valuation signals for MIL:ARBS:

  • Beneish M-Score: -2.15
  • GF Value™: €2.91 vs. price of €3.04 (4.5% above fair value)
  • GF Score™: 77/100

No single metric tells the full story. See the MIL:ARBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Arterra Bioscience SpA Business Description

Address via Benedetto Brin, 69, Napoli, ITA, 80142
Arterra Bioscience SpA is a biotechnology company focused on the research and development of ingredients and natural solutions. It engages in the development of technological platforms, employed in the screening of active compounds for different industrial applications; setting up of new extraction processes, aimed at improving the sustainability and yield of interesting compounds; and production of high-tech raw materials with application in different industrial fields.
77GF Score

Get the complete analysis for MIL:ARBS

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.04
Price
€2.91
GF Value